Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Control Intervention1: Vitamin D3 ( Cholecalciferol VITAMIN D3)
60,000 I U/ weekly for 5 Weeks
2 Vitamin K2-7 100 mcg / day for 5
Sponsors
Suraksha Pharma Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1. Participants of either sex, 20 to 60 years of age who are at high risk. High-risk individuals are defined as all health care professionals in hospitals, clinics, and emergency rooms, and medical facilities involved in management of COVID -19 patients. (Doctors, nursing staff, paramedical staff, ambulance staff, other hospital staff, ward attendees coming in contact with COVID -19 patients). 2. Participants who are negative for RT-PCR test for COVID-19 infection 3. Participants who are willing to provide inform consent and willing to come for schedule follow up visit. 4. Participant not having contra indication to take Vitamin D, 5. Participants having no COVID- 19 infection clinically. 6. Signed informed consent, demonstrating that the subject understands the procedures required for the study and the purpose of the study.
Exclusion criteria
Exclusion criteria: 1 Participants with known allergy or contraindication to Vitamin D ,Vitamin K2-7 & Magnesium . 2 History of having received any investigational drug in the preceding one month. 3 History of taking any kind of formulation or any other form of therapy for COVID- 19 prophylaxis. 4 Unwilling to come for regular follow-up for the entire duration of the study. 5 Any condition that, in the opinion of the investigator, does not justify the subjectâ??s inclusion in the study. 6 Participants participating in other clinical study. 7 Participant receiving other immune enhancers. 8 Refusal to sign informed consent form 9 Any previous positive test for COVID-19 by RT- PCR 10 Symptomatic for COVID-19
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study the safety and efficacy of Vitamin D3, Vitamin K2-7 & magnesium , in prevention of COVID 19 infection in health care professional (HCP)Timepoint: Development of COVID- 19 infection in 5 weeks study period . | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Prevention of COVID-19 measured by negative testing with RT-PCR( In symptomatic participants ) [Time Frame 5 weeks] 2. To determine if treatment with Vitamin D can prevent COVID-19 infection [ Time Frame 5 week] Timepoint: 5 Weeks | — |
Countries
India
Contacts
Public ContactAVN Sridhar
suraksha pharma private limited
Outcome results
None listed